Maribavir drug study compares japanese and caucasian adults
NCT ID NCT04497883
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-stage study tested a single dose of the drug maribavir in 24 healthy adults—12 of Japanese descent and 12 of non-Hispanic Caucasian descent. The goal was to see if the drug behaves differently in these groups and to check safety. Participants took different doses to understand how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- maribavir
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PPD Development, LP
Las Vegas, Nevada, 89113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 10-second sprint may reveal who gains the most muscle from weight training
- Can a needle and a zap boost athletic performance? a trial puts five nerve-stimulation patterns to the test.
- Can an inhaled powder stop lung scarring? a safety trial begins
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Could a gentle buzz behind the ears tune your heart's rhythm?
- Training Non-Radiology staff to take X-Rays: a feasibility test